Celltrion, Inc. (068270.KS)
KRW 193100.0
(-3.06%)
KRW 193100.0
(-3.06%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1325.8 Billion KRW | 449.8% |
| 2022 | 241.14 Billion KRW | 154.32% |
| 2021 | -443.97 Billion KRW | -592.7% |
| 2020 | 90.1 Billion KRW | 277.48% |
| 2019 | -50.77 Billion KRW | -147.89% |
| 2018 | 106.01 Billion KRW | -52.19% |
| 2017 | 221.71 Billion KRW | -45.99% |
| 2016 | 410.53 Billion KRW | -36.44% |
| 2015 | 645.93 Billion KRW | -12.32% |
| 2014 | 736.69 Billion KRW | 10.17% |
| 2013 | 668.7 Billion KRW | 22.5% |
| 2012 | 545.86 Billion KRW | 48.5% |
| 2011 | 367.58 Billion KRW | 49.53% |
| 2010 | 245.82 Billion KRW | 5.71% |
| 2009 | 232.54 Billion KRW | 0.4% |
| 2008 | 231.63 Billion KRW | 802.77% |
| 2007 | 25.65 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 1432.93 Billion KRW | 8.08% |
| 2024 Q2 | 1269.99 Billion KRW | -11.37% |
| 2023 Q2 | 213.37 Billion KRW | -24.35% |
| 2023 Q3 | 528.32 Billion KRW | 147.61% |
| 2023 Q1 | 282.05 Billion KRW | 16.97% |
| 2023 Q4 | 1325.8 Billion KRW | 150.94% |
| 2023 FY | 1325.8 Billion KRW | 449.8% |
| 2022 Q3 | 221.73 Billion KRW | -14.27% |
| 2022 Q4 | 241.14 Billion KRW | 8.75% |
| 2022 Q2 | 258.65 Billion KRW | 163.95% |
| 2022 FY | 241.14 Billion KRW | 154.32% |
| 2022 Q1 | -404.45 Billion KRW | 8.9% |
| 2021 Q3 | -179.5 Billion KRW | -191.21% |
| 2021 Q4 | -443.97 Billion KRW | -147.33% |
| 2021 Q1 | 16.92 Billion KRW | -81.22% |
| 2021 Q2 | -61.64 Billion KRW | -464.22% |
| 2021 FY | -443.97 Billion KRW | -592.7% |
| 2020 FY | 90.1 Billion KRW | 277.48% |
| 2020 Q2 | -169.48 Billion KRW | -71.99% |
| 2020 Q1 | -98.54 Billion KRW | -94.1% |
| 2020 Q4 | 90.1 Billion KRW | 173.16% |
| 2020 Q3 | -123.16 Billion KRW | 27.33% |
| 2019 Q3 | -51.51 Billion KRW | -161.31% |
| 2019 Q2 | 84.02 Billion KRW | -26.72% |
| 2019 FY | -50.77 Billion KRW | -147.89% |
| 2019 Q1 | 114.65 Billion KRW | 8.15% |
| 2019 Q4 | -50.77 Billion KRW | 1.44% |
| 2018 Q1 | 153.02 Billion KRW | -30.98% |
| 2018 Q4 | 106.01 Billion KRW | -42.02% |
| 2018 Q3 | 182.83 Billion KRW | -7.83% |
| 2018 FY | 106.01 Billion KRW | -52.19% |
| 2018 Q2 | 198.36 Billion KRW | 29.63% |
| 2017 FY | 221.71 Billion KRW | -45.99% |
| 2017 Q2 | 378.49 Billion KRW | -7.05% |
| 2017 Q3 | 316.92 Billion KRW | -16.27% |
| 2017 Q4 | 221.71 Billion KRW | -30.04% |
| 2017 Q1 | 407.18 Billion KRW | -0.82% |
| 2016 Q3 | 517.15 Billion KRW | -8.21% |
| 2016 Q4 | 410.53 Billion KRW | -20.62% |
| 2016 Q1 | 511.49 Billion KRW | -20.81% |
| 2016 FY | 410.53 Billion KRW | -36.44% |
| 2016 Q2 | 563.44 Billion KRW | 10.16% |
| 2015 Q4 | 645.93 Billion KRW | -2.4% |
| 2015 Q3 | 661.84 Billion KRW | 3.87% |
| 2015 FY | 645.93 Billion KRW | -12.32% |
| 2015 Q2 | 637.19 Billion KRW | -18.0% |
| 2015 Q1 | 777.1 Billion KRW | 5.49% |
| 2014 Q3 | 696.49 Billion KRW | -13.51% |
| 2014 Q2 | 805.26 Billion KRW | 0.74% |
| 2014 FY | 736.69 Billion KRW | 10.17% |
| 2014 Q4 | 736.69 Billion KRW | 5.77% |
| 2014 Q1 | 799.33 Billion KRW | 19.53% |
| 2013 FY | 668.7 Billion KRW | 22.5% |
| 2013 Q4 | 668.7 Billion KRW | 2.8% |
| 2013 Q3 | 650.5 Billion KRW | -8.49% |
| 2013 Q2 | 710.85 Billion KRW | 51.75% |
| 2013 Q1 | 468.44 Billion KRW | -14.18% |
| 2012 Q4 | 545.86 Billion KRW | 0.0% |
| 2012 Q1 | 379.5 Billion KRW | 0.0% |
| 2012 FY | 545.86 Billion KRW | 48.5% |
| 2011 Q1 | 283.05 Billion KRW | 15.15% |
| 2011 FY | 367.58 Billion KRW | 49.53% |
| 2011 Q3 | 309.18 Billion KRW | 5.18% |
| 2011 Q2 | 293.96 Billion KRW | 3.85% |
| 2010 Q1 | 249.44 Billion KRW | 7.27% |
| 2010 Q4 | 245.82 Billion KRW | -10.09% |
| 2010 FY | 245.82 Billion KRW | 5.71% |
| 2010 Q3 | 273.4 Billion KRW | 13.17% |
| 2010 Q2 | 241.59 Billion KRW | -3.15% |
| 2009 Q3 | 200.82 Billion KRW | -5.31% |
| 2009 Q2 | 212.07 Billion KRW | -12.63% |
| 2009 Q1 | 242.72 Billion KRW | 4.79% |
| 2009 FY | 232.54 Billion KRW | 0.4% |
| 2009 Q4 | 232.54 Billion KRW | 15.8% |
| 2008 Q3 | 250.57 Billion KRW | 1734.28% |
| 2008 Q1 | 20.12 Billion KRW | 0.0% |
| 2008 FY | 231.63 Billion KRW | 802.77% |
| 2008 Q2 | 13.66 Billion KRW | -32.11% |
| 2008 Q4 | 231.63 Billion KRW | -7.56% |
| 2007 Q3 | 15.41 Billion KRW | 2.09% |
| 2007 Q1 | 11.96 Billion KRW | 0.0% |
| 2007 Q2 | 15.1 Billion KRW | 26.21% |
| 2007 FY | 25.65 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ORIENT BIO Inc. | -3.06 Billion KRW | 43296.72% |
| Green Cross Holdings Corporation | 1105.62 Billion KRW | -19.914% |
| Green Cross Holdings Corporation | 674.31 Billion KRW | -96.615% |
| Pharmicell Co., Ltd. | -10.69 Billion KRW | 12494.962% |
| Green Cross Corporation | 674.31 Billion KRW | -96.615% |
| GeneOne Life Science, Inc. | 8.04 Billion KRW | -16372.192% |
| Samsung Biologics Co.,Ltd. | 1541.39 Billion KRW | 13.986% |
| SK bioscience Co.,Ltd. | -106.45 Billion KRW | 1345.451% |
| SK Biopharmaceuticals Co., Ltd. | -61.64 Billion KRW | 2250.541% |
| Prestige BioPharma Limited | -129.76 Billion KRW | 1121.691% |